!!!CARE!Checklist!of!information!to!include!when!writing!a!case!report!

Topic Item Checklist item description Reported on Line

Title 1 The dia nosis or inter ention of primary focus fo o ed y the words “case report” . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 1, Line 3
Key Words 2 2 to 5 key words that identify dia noses or inter entions in this case report inc udin case report . . . Page No 3, Line 100-103
Abstract 3a ntroduction hat is uni ue a out this case and hat does it add to the scientific iterature . . . . . . . . . . . . . . . . Page No 5, Line 163-168
n e e en e 3b ain symptoms and or important clinical findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 3, Line 77-81
3c The main diagnoses, therapeutic interventions, and outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 3, Line 83-89
3d Conclusion—What is the main “take-away” lesson s from this case? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 3, Line 96-99
Introduction 4 One or two paragraphs summarizing why this case is unique may include references . . . . . . . . . . . . Page No 5, Line 153-168
Patient Information 5a De-identified patient specific information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 173-175
5b rimary concerns and symptoms of the patient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 173-175
5c Medical, family, and psycho-social history including relevant genetic information . . . . . . . . . . . . . . . . . Page No 6, Line 173-175
5d Relevant past interventions ith outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 173-175
Clinical Findings 6 Describe si nificant physical examination (PE) and important clinical findings. . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 177-181
Timeline 7 Historica and current information from this episode of care organized as a timeline . . . . . . . . . . . . . . . Page No 6, Line 177-181
Diagnostic 8a Diagnostic testin (such as PE, laboratory testing, imaging, surveys). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 177-181
Assessment
8b Diagnostic challenges (such as access to testin , financial, or cultural) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Not applicable
8c Diagnosis including other diagnoses considered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 177-181
8d Prognosis (such as staging in oncology) where applicable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Not applicable
Therapeutic 9a Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) . . . . . . . . . . . . . . . . . . . . Page No 6, Line 186-200
Intervention
9b Administration of therapeutic intervention (such as dosage, strength, duration) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 186-200
9c Changes in therapeutic intervention (with rationale) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 186-200
Follow-up and 10a Clinician and patient-assessed outcomes (if a ai a e) . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . Page . . . . . . . No
. . 6, Line 202- Page No 7, Line 212
Outcomes
10b Important follow-up diagnostic and other test results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Page . . . . . . .No. 6, Line 202- Page No 7, Line 212
10c Intervention adherence and tolerability (How was this assessed?) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Not applicable
10d Adverse and unanticipated events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page No 6, Line 203
Discussion 11a A scientific discussion of the strengths limitations associated with this case report . . . . . . . . . . . . . . . . . . . . . . . Page No 10, Line 327-333
11b Discussion of the relevant medical literature i e e en e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page . . . . . No 7, Line 214 - Page 10 Line 339
11c The scientific rationale for any conclusions (including assessment of possible causes) . . . . . . . . . . . . . . . . . . . . . . . . Page No 10, Line 340-343
11d The primary “take-away” lessons of this case report ithout references in a one para raph conc usion . . . . . . . Page No 10, Line 340-343
Patient Perspective 12 The patient should share their perspective in one to t o para raphs on the treatment s they received . . . . . . . . Page No 7, Line 212
Informed Consent 13 Did the patient give informed consent? Please provide if requested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yes X No